Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Protagonist Therapeutics Inc (PTGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 198,743
  • Shares Outstanding, K 24,090
  • Annual Sales, $ 20,060 K
  • Annual Income, $ -36,960 K
  • 36-Month Beta 3.75
  • Price/Sales 9.81
  • Price/Cash Flow N/A
  • Price/Book 1.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.12
  • Low Estimate -0.69
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -41.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.07 +4.09%
on 09/14/18
10.50 -20.00%
on 08/30/18
-0.66 (-7.28%)
since 08/20/18
3-Month
6.57 +27.85%
on 07/02/18
11.90 -29.41%
on 08/09/18
+1.31 (+18.48%)
since 06/20/18
52-Week
5.50 +52.73%
on 05/14/18
23.97 -64.96%
on 03/09/18
-8.92 (-51.50%)
since 09/20/17

Most Recent Stories

More News
Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on Sept. 15, 2018, it issued an inducement award to Carter King, the Company's recently hired Vice President of Business Development, in...

PTGX : 8.40 (+1.82%)
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the receipt of a Phase 2 Small Business Innovation Research (SBIR) Grant from the National Heart, Lung and Blood Institute of the National...

PTGX : 8.40 (+1.82%)
Protagonist Therapeutics Reports Granting of Inducement Award

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 15, 2018, it issued an inducement award to Niall Murphy, the Company's recently hired Vice President, Corporate Controller, in...

PTGX : 8.40 (+1.82%)
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates

Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -36.67% and 36.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?...

PTGX : 8.40 (+1.82%)
Protagonist Therapeutics: 2Q Earnings Snapshot

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Tuesday reported a loss of $8.7 million in its second quarter.

PTGX : 8.40 (+1.82%)
Protagonist Therapeutics Reports Second Quarter 2018 Financial Results

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the second quarter ended June 30, 2018.

PTGX : 8.40 (+1.82%)
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced results from an independent blinded re-analysis of the Phase 2 PROPEL study of oral alpha-4-beta-7 integrin antagonist PTG-100 for the treatment...

PTGX : 8.40 (+1.82%)
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that results of a Phase 1 study in healthy volunteers and supportive pre-clinical data for the Company's novel injectable hepcidin mimetic,...

PTGX : 8.40 (+1.82%)
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors

Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Bryan Giraudo to its Board of Directors. Mr. Giraudo currently serves as Chief Financial Officer of Gossamer Bio and was...

PTGX : 8.40 (+1.82%)
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down

Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.

PTGX : 8.40 (+1.82%)
LGND : 257.78 (-2.42%)
PBYI : 47.55 (-0.52%)
RHHBY : 30.6000 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PTGX with:

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

2nd Resistance Point 8.66
1st Resistance Point 8.53
Last Price 8.40
1st Support Level 8.21
2nd Support Level 8.02

See More

52-Week High 23.97
Fibonacci 61.8% 16.91
Fibonacci 50% 14.73
Fibonacci 38.2% 12.56
Last Price 8.40
52-Week Low 5.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar